OLD Category: GeoMx DSP

November 1, 2022 / J Histotechnol

  • Chiriboga L, Callis GM, Wang Y, Chlipala E
November 1, 2022 / Cancers

  • De Filippis R, Wölflein G, Um IH, Caie PD, Warren S, White A, Suen E, To E, Arandjelović O, Harrison DJ
October 31, 2022 / mBio

  • Kong W, Montano M, Corley MJ, Helmy E, Kobayashi H, Kinisu M, Suryawanshi R, Luo X, Royer LA, Roan NR, Ott M, Ndhlovu LC, Greene WC
October 31, 2022 / Front Immunol

  • Hu B, Sajid M, Lv R, Liu L, Sun C
October 27, 2022 / Mucosal Immunol

  • Cavounidis A, Pandey S, Capitani M, Friedrich M, Cross A, Gartner L, Aschenbrenner D, Kim-Schulze S, Lam YK, Berridge G, McGovern DPB, Kessler B, Fischer R, Klenerman P, Hester J, Issa F, Torres EA, Powrie F, Gochuico BR, Gahl WA, Cohen L, Uhlig HH
October 26, 2022 / Cells

  • Lee J, Kim CM, Cha JH, Park JY, Yu YS, Wang HJ, Sung PS, Jung ES, Bae SH
October 18, 2022 / Genes

  • Maranian M, Snead M.
October 17, 2022 / Clin Transl Med

  • Ling Y, Zhong J, Weng Z, Lin G, Liu C, Pan C, Yang H, Wei X, Xie X, Wei X, Zhang H, Wang G, Fu J, Wen J
October 14, 2022 / Clin Cancer Res

  • Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, Graham R, Akarca A, Lips E, Naidoo K, Wesseling J, Marafioti T, Cheang M, Gillett C, Wu Y, Khan A, Melcher A, Salgado R, Dowsett M, Tutt A, Roxanis I, Haider S, Irshad S
Purpose:: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+HER2– breast cancer disease. Experimental Design:: Following pathology review, 153 patients were identified as having…
October 13, 2022 / Front Oncol

  • Schoenfeld DA, Merkin RD, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm DL, Kluger HM
October 10, 2022 / Nat Commun

  • Zhang Q, Abdo R, Iosef C, Kaneko T, Cecchini M, Han VK, Li SS
October 8, 2022 / Cancers (Basel)

  • Kumar V, Randhawa P, Bilodeau R, Mercola D, McClelland M, Agrawal A, Nguyen J, Castro P, Ittmann MM, Rahmatpanah F